A novel model of the continual reassessment method in Phase I trial

For the model-based designs, the continual reassessment method (CRM) is widely used to identify the maximum tolerated dose (MTD) in phase I clinical trials. To improve the performance of classic CRM models, we propose a new CRM and its dose-toxicity probability function based on the Cox model whatev...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Weijia, Lei, Wanni, Zhu, Xiaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050314/
https://www.ncbi.nlm.nih.gov/pubmed/36977709
http://dx.doi.org/10.1038/s41598-023-28148-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050314/
https://www.ncbi.nlm.nih.gov/pubmed/36977709
http://dx.doi.org/10.1038/s41598-023-28148-4

Ejemplares similares